Literature DB >> 7995194

Clinical significance of plasma endothelin-1 in patients with chronic liver disease.

H Matsumoto1, J Uemasu, M Kitano, H Kawasaki.   

Abstract

To determine the clinical significance of plasma endothelin-1 in chronic liver disease, these levels were measured by radioimmunoassay. The plasma endothelin-1 levels in patients with cirrhosis (N = 16) (2.04 +/- 0.25 pg/ml) and patients with hepatocellular carcinoma (N = 22) (2.23 +/- 0.17 pg/ml) increased significantly compared with controls (N = 16) (1.17 +/- 0.17 pg/ml) and patients with chronic hepatitis (N = 11) (1.09 +/- 0.19 pg/ml) (P < 0.01). The presence of ascites rather than tumor volume was associated with a significant elevation of endothelin-1. Endothelin-1 showed significant negative correlations with parameters of hepatic function, including indocyanine green clearance, serum albumin, and prothrombin time. Although endothelin-1 was not correlated with plasma renin activity and plasma endotoxin, it demonstrated a significant positive correlation with the plasma level of atrial natriuretic peptide (r = 0.42, P < 0.01). These findings demonstrate that plasma endothelin-1 increased in proportion to the severity of liver damage and may be causally related with the derangement of systemic/renal hemodynamics and fluid and electrolyte homeostasis seen in advanced liver disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7995194     DOI: 10.1007/BF02087707

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  Integrated cardiac, renal, and endocrine actions of endothelin.

Authors:  W L Miller; M M Redfield; J C Burnett
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

2.  Increased plasma endothelin levels in patients with liver cirrhosis.

Authors:  J Uemasu; H Matsumoto; H Kawasaki
Journal:  Nephron       Date:  1992       Impact factor: 2.847

3.  Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells.

Authors:  M Kohno; K Yasunari; K Yokokawa; K Murakawa; T Horio; T Takeda
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

4.  Role of vasopressin in abnormal water excretion in cirrhotic patients.

Authors:  D Bichet; V Szatalowicz; C Chaimovitz; R W Schrier
Journal:  Ann Intern Med       Date:  1982-04       Impact factor: 25.391

5.  The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase).

Authors:  J Vijayaraghavan; A G Scicli; O A Carretero; C Slaughter; C Moomaw; L B Hersh
Journal:  J Biol Chem       Date:  1990-08-25       Impact factor: 5.157

6.  Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor.

Authors:  G de Nucci; R Thomas; P D'Orleans-Juste; E Antunes; C Walder; T D Warner; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  Endothelin: a potent renal and systemic vasoconstrictor peptide.

Authors:  A J King; B M Brenner; S Anderson
Journal:  Am J Physiol       Date:  1989-06

8.  Plasma endothelin levels in cirrhotic subjects.

Authors:  F Veglio; G Pinna; R Melchio; F Rabbia; M Panarelli; B Gagliardi; L Chiandussi
Journal:  J Hepatol       Date:  1992-05       Impact factor: 25.083

9.  Endothelin is a potent secretagogue for atrial natriuretic peptide in cultured rat atrial myocytes.

Authors:  Y Fukuda; Y Hirata; H Yoshimi; T Kojima; Y Kobayashi; M Yanagisawa; T Masaki
Journal:  Biochem Biophys Res Commun       Date:  1988-08-30       Impact factor: 3.575

10.  Secretory mechanism of immunoreactive endothelin in cultured bovine endothelial cells.

Authors:  T Emori; Y Hirata; K Ohta; M Shichiri; F Marumo
Journal:  Biochem Biophys Res Commun       Date:  1989-04-14       Impact factor: 3.575

View more
  5 in total

Review 1.  Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension.

Authors:  H Reynaert; M G Thompson; T Thomas; A Geerts
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

2.  Onset ages of hepatopulmonary syndrome and pulmonary hypertension in patients with biliary atresia.

Authors:  Takehisa Ueno; Ryuta Saka; Yuichi Takama; Hiroaki Yamanaka; Yuko Tazuke; Kazuhiko Bessho; Hiroomi Okuyama
Journal:  Pediatr Surg Int       Date:  2017-09-04       Impact factor: 1.827

3.  Hyperendothelinemia and ICG clearance in alcoholic and nonalcoholic cirrhosis.

Authors:  Shigeo Maruyama; Chisato Hirayama; Satoru Yamamoto; Masaharu Koda; Akihiro Udagawa; Yoshiro Kadowaki; Masayuki Inoue; Atsushi Sagayama; Kensuke Umeki
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

4.  Plasma endothelin-1 levels in patients with biliary atresia: possible role in development of portal hypertension.

Authors:  V Chongsrisawat; P Chatchatee; R Samransamruajkit; P Vanapongtipagorn; P Chottivittayatarakorn; Y Poovorawan
Journal:  Pediatr Surg Int       Date:  2003-05-13       Impact factor: 1.827

5.  Effects of endothelin-1 on hepatic stellate cell proliferation, collagen synthesis and secretion, intracellular free calcium concentration.

Authors:  Chuan-Yong Guo; Jian-Ye Wu; Yun-Bin Wu; Min-Zhang Zhong; Han-Ming Lu
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.